{
  "abstract": "Pembrolizumab plus chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in the phase 3 randomized KEYNOTE-355 study in participants with previously untreated, advanced triple-negative breast cancer (TNBC) with PD-L1 combined positive score (CPS) ≥ 10. Among participants with clinical benefit from pembrolizumab plus chemotherapy, discontinuation of chemotherapy before pembrolizumab for any reason was associated with similar median PFS and OS to that in the overall population. Additionally, we further characterized immune-mediated adverse events (AEs) in KEYNOTE-355. Most immune-mediated AEs were manageable with treatment interruption and supportive care. In participants treated with pembrolizumab plus chemotherapy with immune-mediated AEs, there appeared to be numerical improvement in efficacy. This analysis provides additional information on the use of pembrolizumab plus chemotherapy as standard-of-care therapy in patients with previously untreated, advanced TNBC with PD-L1 CPS ≥ 10. This trial is registered at ClinicalTrials.gov (NCT02819518; registration date, June 28, 2016).",
  "abstract_shown": true,
  "affiliations": [
    "City of Hope Comprehensive Cancer Center",
    "Princess Margaret Cancer Centre, University Health Network, University of Toronto",
    "Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London",
    "Breast Cancer and Reconstructive Surgery Department, Maria Sklodowska-Curie National Research Institute of Oncology",
    "Seoul National University Hospital, Seoul National University College of Medicine, Cancer Research Institute, Seoul National University",
    "Hospital PICASO",
    "Bradford Hill Research Center",
    "Nagoya City University",
    "Republican Clinical Oncology Dispensary of the Ministry of Public Health of Bashkortostan Republic",
    "Instituto Brasileiro de Controle do Câncer",
    "Latin American Cooperative Oncology Group (LACOG)",
    "Gynecological and Breast Oncology, Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda., Avenida Brigadeiro Luís Antônio",
    "Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, and The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne",
    "Hospital Universitario Ramón y Cajal",
    "Oncomedica",
    "Department of Oncology, University of Debrecen",
    "Maria Sklodowska-Curie National Research Institute of Oncology",
    "Merck & Co., Inc.",
    "International Breast Cancer Center, Pangaea Oncology, Quiron Group, Barcelona, Spain; IOB Madrid, Hospital Beata Maria Ana, Madrid, Spain; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 21,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Hope S. Rugo"
    },
    {
      "affs": [
        1
      ],
      "name": "David W. Cescon"
    },
    {
      "affs": [
        2
      ],
      "name": "Peter Schmid"
    },
    {
      "affs": [
        3
      ],
      "name": "Zbigniew Nowecki"
    },
    {
      "affs": [
        4
      ],
      "name": "Seock-Ah Im"
    },
    {
      "affs": [
        5
      ],
      "name": "Mastura Md Yusof"
    },
    {
      "affs": [
        6
      ],
      "name": "Carlos Gallardo"
    },
    {
      "affs": [
        7
      ],
      "name": "Hiroji Iwata"
    },
    {
      "affs": [
        8
      ],
      "name": "Oleg Lipatov"
    },
    {
      "affs": [
        9
      ],
      "name": "Felipe Cruz"
    },
    {
      "affs": [
        10
      ],
      "name": "Carlos Henrique Barrios"
    },
    {
      "affs": [
        11
      ],
      "name": "Roberto Hegg"
    },
    {
      "affs": [
        12
      ],
      "name": "Sherene Loi"
    },
    {
      "affs": [
        13
      ],
      "name": "Maria Gion"
    },
    {
      "affs": [
        14
      ],
      "name": "Marco Torregroza Otero"
    },
    {
      "affs": [
        15
      ],
      "name": "Péter Árkosy"
    },
    {
      "affs": [
        16
      ],
      "name": "Rafal Tarnawski"
    },
    {
      "affs": [
        17
      ],
      "name": "Lili Yao"
    },
    {
      "affs": [
        17
      ],
      "name": "Jaime Mejia"
    },
    {
      "affs": [
        17
      ],
      "name": "Wilbur Pan"
    },
    {
      "affs": [
        18
      ],
      "name": "Javier Cortés"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/cktee6hc02cnb.bib",
  "cited_by": 0,
  "doi": "10.1038/s41523-026-00971-8",
  "fulltext_url": "https://doi.org/10.1038/s41523-026-00971-8",
  "id": "cktee6hc02cnb",
  "issns": [
    "2374-4677"
  ],
  "landing_url": "https://doi.org/10.1038/s41523-026-00971-8",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC254-282"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7166110622",
  "pdf_url": "https://www.nature.com/articles/s41523-026-00971-8_reference.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-06-01",
  "publisher": "Nature Portfolio",
  "ris": "https://research.draconitic.com/paper/cktee6hc02cnb.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T13:46:11Z",
      "native_id": "80b4b58fbc414444b419a61027ed9116",
      "source": "doaj",
      "url": "https://doi.org/10.1038/s41523-026-00971-8"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events",
  "title_text": "Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:46:11Z",
  "url": "https://research.draconitic.com/paper/cktee6hc02cnb",
  "venue": "npj Breast Cancer",
  "versions": []
}